IASR

American Foundation for Suicide Prevention Invests $6.44M in Scientific Research to Prevent Leading Cause of Death

Retrieved on: 
Thursday, October 21, 2021
Research, Volunteering, AFSP, American Foundation for Suicide Prevention, Mental health, Genetics, Twitter, Darkness, Southern African Development Community intervention in Lesotho, YouTube, Suicide, Annual report, Instagram, CEO, Multimedia, National Institute of Mental Health, National Institute, Hope, IASR, School, Culture, Education, Neuroscience, Pharmaceutical industry

NEW YORK, Oct. 21, 2021 /PRNewswire/ --The largest private funder of suicide prevention research, the American Foundation for Suicide Prevention (AFSP), today announced 37 new research grants totaling $6.44 million in new research for 2021; and $23.7 million for all current studies.

Key Points: 
  • NEW YORK, Oct. 21, 2021 /PRNewswire/ --The largest private funder of suicide prevention research, the American Foundation for Suicide Prevention (AFSP), today announced 37 new research grants totaling $6.44 million in new research for 2021; and $23.7 million for all current studies.
  • "It's scientific research that informs AFSP's education programs that are presented in schools, workplaces, and other settings across the country.
  • Some areas examined by our newest grants include:
    The AFSP research grants program is international, supporting the best research globally.
  • The American Foundation for Suicide Prevention is dedicated to saving lives and bringing hope to those affected by suicide.

Seelos Therapeutics to Present a Poster on SLS-002 (Intranasal Racemic Ketamine) at the 2021 IASR/AFSP International Summit on Suicide Research

Retrieved on: 
Friday, October 1, 2021
EDT, CNS, Post-traumatic stress disorder, Therapy, Ketamine, Nature, National Suicide Prevention Lifeline, Risk, Major depressive disorder, Annual report, Agency for Healthcare Research and Quality, Conference, Private Securities Litigation Reform Act, National Suicide Prevention Week, Depression, Sanfilippo syndrome, U.S. Securities and Exchange Commission, Patient, Movement disorders, ASIB, Poster, Disorder, Central nervous system, Degenerative disease, MDD, Disease, CEO, Parkinson's disease, Company, Program, Lists of diseases, Agency, Trial of the century, Amyotrophic lateral sclerosis, COVID-19, ALS, Research, Psychiatry, PTSD, Imminent Risk, Nasdaq, IASR, Pharmaceutical industry

If you or a loved one are having thoughts of suicide, please seek immediate medical help, go to your nearest emergency room, or call the National Suicide Prevention Lifeline at 1-800-273-8255.

Key Points: 
  • If you or a loved one are having thoughts of suicide, please seek immediate medical help, go to your nearest emergency room, or call the National Suicide Prevention Lifeline at 1-800-273-8255.
  • SLS-002is intranasal racemic ketamine with two investigational new drug applications ("INDs").
  • SLS-002 was originally derived from a Javelin Pharmaceuticals, Inc./Hospira, Inc. program with 16 clinical studies involving approximately 500 subjects.
  • SLS-002 looks to address an unmet need for an efficacious drug to treat suicidality in the United States.